Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
Shockwaves from Monday's AI stock panic in the US were largely confined to two ASX industries.
video
What does a weak Aussie dollar mean for investors?
Morningstar Investment Management's Chief Investment Officer for Asia Pacific weighs in on the weak Aussie dollar and what this could mean for investors.
stocks
AI stock rout: The US selloff in 4 charts
Worries about Western AI dominance permeated the markets, with Nvidia stock plunging 17% alongside other chipmakers, utilities, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,757.30 | 56.60 | 0.65% |
| CAC 40 | 7,872.48 | 24.89 | -0.32% |
| DAX 40 | 21,637.53 | 206.95 | 0.97% |
| Dow JONES (US) | 44,713.52 | 136.83 | -0.31% |
| FTSE 100 | 8,557.81 | 23.94 | 0.28% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,632.32 | 101.26 | -0.51% |
| Nikkei 225 | 39,593.72 | 178.94 | 0.45% |
| NZX 50 Index | 12,924.13 | 78.91 | -0.61% |
| S&P 500 | 6,039.31 | 28.39 | -0.47% |
| S&P/ASX 200 | 8,504.00 | 57.00 | 0.67% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |